Information Provided By: 
Fly News Breaks for May 8, 2017
EGRX
May 8, 2017 | 13:56 EDT
Piper Jaffray analyst David Amsellem raised his price target for Eagle Pharmaceuticals to $118 following the company's Q1 results. Eagle's "sustainable" cash flows from Bendeka, along with eventual contribution from Ryanodex in exertional heat stroke and drug-induced hyperthermia, as well as other pipeline assets, position Eagle well for "transformative longer-term earnings growth," Amsellem tells investors in a post-earnings research note. He reiterates an Overweight rating on the shares.
News For EGRX From the Last 2 Days
There are no results for your query EGRX
